Diabetes Mellitus Clinical Trial
— E4DMMCOfficial title:
ECHO for Diabetes and Multiple Chronic Conditions Study
Diabetes mellitus is a chronic condition that affects the body's ability to process sugar effectively, which over time can increase the risk of heart disease, high blood pressure, and kidney damage. Other chronic conditions include high cholesterol, obesity, and depression. Persons with diabetes mellitus and multiple chronic conditions (DMMC) face higher risks of losing physical or mental function, experiencing other chronic conditions, and death. Most of the residents of New Mexico (NM) belong to groups at risk for developing DMMC. Finding quality healthcare is a key factor, as NM also ranks among the largest, poorest, and most rural states. Primary care providers (PCPs) most often treat DMMC patients, but healthcare teams can lack confidence in managing these complex patients and struggle to keep up with recommended guidelines. This Project ECHO model (ECHO) for DMMC, a telehealth intervention for healthcare teams, can lead to lower blood sugar levels in DMMC patients being treated at NM primary care clinics. ECHO is a "telementoring" program that trains healthcare teams to provide specialized medical care at their local clinics. This is done by connecting healthcare teams with specialist mentors at academic medical centers through videoconferencing sessions. During ECHO program sessions, groups of healthcare teams hear lectures on key topics in DMMC care from experts, and then give presentations of anonymous patient cases by a healthcare teams for discussion and to receive recommendations. This clinical pragmatic trial aims to learn if the intervention will improve patient blood sugar levels in persons with DMMC who are being treated at selected health clinic sites throughout New Mexico. The study aims to answer: - Whether a 0.5% drop in HbA1c on average can be achieved in the group whose healthcare teams are receiving the ECHO intervention compared to the comparator group, whose providers will not receive the intervention. - Whether the rate of an individual's HbA1c was greater than 8.5% at the baseline will be reduced by 15% at the end of the intervention. Researchers will compare health data for patients empaneled to healthcare teams in the study and the usual care comparator group both before and after the intervention period to see whether the ECHO model has a positive influence on test results.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | June 30, 2028 |
Est. primary completion date | September 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 89 Years |
Eligibility | Inclusion criteria: - Twenty PMS sites with the highest patient volume. - All members of the PMS sites (participants) healthcare teams between 18 and 89 years of age, all genders, and all ethnicities. Exclusion criteria: - There is no exclusion criteria. |
Country | Name | City | State |
---|---|---|---|
United States | Presbyterian Medical Services | Santa Fe | New Mexico |
Lead Sponsor | Collaborator |
---|---|
University of New Mexico | Patient-Centered Outcomes Research Institute, Presbyterian Medical Services |
United States,
Arora S, Kalishman S, Dion D, Som D, Thornton K, Bankhurst A, Boyle J, Harkins M, Moseley K, Murata G, Komaramy M, Katzman J, Colleran K, Deming P, Yutzy S. Partnering urban academic medical centers and rural primary care clinicians to provide complex chronic disease care. Health Aff (Millwood). 2011 Jun;30(6):1176-84. doi: 10.1377/hlthaff.2011.0278. Epub 2011 May 19. — View Citation
Arora S, Kalishman SG, Thornton KA, Komaromy MS, Katzman JG, Struminger BB, Rayburn WF, Bradford AM. Project ECHO: A Telementoring Network Model for Continuing Professional Development. J Contin Educ Health Prof. 2017 Fall;37(4):239-244. doi: 10.1097/CEH.0000000000000172. Erratum In: J Contin Educ Health Prof. 2018 Winter;38(1):78. — View Citation
Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011 Jun 9;364(23):2199-207. doi: 10.1056/NEJMoa1009370. Epub 2011 Jun 1. — View Citation
Bouchonville MF, Hager BW, Kirk JB, Qualls CR, Arora S. ENDO ECHO IMPROVES PRIMARY CARE PROVIDER AND COMMUNITY HEALTH WORKER SELF-EFFICACY IN COMPLEX DIABETES MANAGEMENT IN MEDICALLY UNDERSERVED COMMUNITIES. Endocr Pract. 2018 Jan;24(1):40-46. doi: 10.4158/EP-2017-0079. — View Citation
Bouchonville MF, Paul MM, Billings J, Kirk JB, Arora S. Taking Telemedicine to the Next Level in Diabetes Population Management: a Review of the Endo ECHO Model. Curr Diab Rep. 2016 Oct;16(10):96. doi: 10.1007/s11892-016-0784-9. — View Citation
MATTHEW F. BOUCHONVILLE, ERIK B. ERHARDT, YURIDIA L. LEYVA, LARISSA MYASKOVSKY, MARK L. UNRUH, SANJEEV ARORA; 1029-P: Building Diabetes Care Capacity in Rural Underserved Communities-A Comparison of Cardiorenal Risk Factor Outcomes in Patients Treated by ECHO-Trained Providers vs. an Academic Medical Center. Diabetes 20 June 2023; 72 (Supplement_1): 1029-P. https://doi.org/10.2337/db23-1029-P
Nelson RG, Pankratz VS, Ghahate DM, Bobelu J, Faber T, Shah VO. Home-Based Kidney Care, Patient Activation, and Risk Factors for CKD Progression in Zuni Indians: A Randomized, Controlled Clinical Trial. Clin J Am Soc Nephrol. 2018 Dec 7;13(12):1801-1809. doi: 10.2215/CJN.06910618. Epub 2018 Nov 15. — View Citation
Paul M, Davila Saad A, Billings J, Blecker S, Bouchonville MF, Berry C. MON-190 Endo ECHO Improves Patient-Reported Measures of Access to Care, Health Care Quality, Self-Care Behaviors, and Overall Quality of Life for Patients with Complex Diabetes in Medically Underserved Areas of New Mexico. J Endocr Soc. 2019 Apr 30;3(Suppl 1):MON-190. doi: 10.1210/js.2019-MON-190. PMCID: PMC6551170.
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | HbA1c levels | HbA1c change over intervention and follow-up for DM patients with 1 or no other chronic condition | At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention. | |
Other | HbA1c levels and disease progression - pre-DM | HbA1c change over intervention and follow-up for pre-DM patients | Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up | |
Other | HbA1c levels and disease progression - newly diagnosed DM | HbA1c change over intervention and follow-up for newly diagnosed DM or DMMC patients who did not have baseline data | At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention. | |
Other | Patient Activation Measure (PAM) | Short form 13-item Patient Activation Measure. The scale is proprietary, and there is no low or high. | Per PMS standard patient survey; during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up | |
Primary | HbA1c trajectory | A decreasing trajectory in patients' HbA1c over time during and following ECHO intervention, reaching an average of 0.5% drop 18 months into intervention compared with comparator | At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention. | |
Primary | HbA1c level in control | 15% decreases in per-patient rate of HbA1c>8.5% by 18 months into intervention, respectively, compared with comparator | At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention. | |
Secondary | Use of any tele-med modalities for patient visits | Percentage of DMMC patients with at least 2 HbA1c tests per year as adherence to recommended DM management across modalities (audio-only vs. videoconference) | Every encounter per EHR during 12 months baseline prior to intervention, during the study period (18 months intervention and up to 18 months follow-up for the intervention arm) | |
Secondary | Hypertension | Patient blood pressure not in control (systolic blood pressure (SBP)>130 and/or diastolic blood pressure (DBP)>80) | Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up | |
Secondary | Cholesterol | Patient low-density lipoprotein LDL-C | Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR | |
Secondary | Kidney function | Estimated glomerular filtration rate (eGFR) and/or urine albumin-creatinine ratio (UACR) | Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR | |
Secondary | Depressive symptoms - Large version | Rate of at least one positive Patient Health Questionnaire (PHQ) -2 per patient per 12-month period. The score ranges from a minimum of 0 and maximum of 6, with a higher score indicating more severe symptoms of major depressive disorder. | Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up | |
Secondary | Depressive symptoms - Small version | Depression screening score trajectory on PHQ-2 (amongst the total population and amongst those with positive PHQ-2) or PHQ-9 (only amongst those with positive PHQ-2) per 12-month period. PHQ-9 score ranges between a minimum of 0 and a maximum of 27, with the higher the score meaning a greater severity of depression. | Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up | |
Secondary | Obesity | Body mass index | Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up | |
Secondary | Receipt of appropriate exams | Eye exams
Foot exams |
Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR | |
Secondary | Rates of prescribing DM meds in accordance with guidelines | DM meds: metformin, sulfonylureas (glipizide, glimepiride, glyburide), glucagon-like peptide-1 receptor agonist (GLP-1RA) (patients with atherosclerotic cardiovascular disease (ASCVD)), sodium-glucose transport protein 2 inhibitors (SGLT2i) (patients with ASCVD, CKD, heart failure), thiazolidinediones (pioglitazone), GLP-1/GIP RA (tirzepatide), and insulin. | Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up | |
Secondary | Rates of prescribing hypertension meds in accordance with guidelines | Hypertension meds: thiazide or thiazide like diuretics, angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACE-I), or dihydropyridine calcium channel blockers (CCB). | Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up | |
Secondary | Rates of prescribing CKD meds in accordance with guidelines | CKD meds: ACE-I or ARB, SGLT2i, or finerenone. | Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up | |
Secondary | Rates of prescribing hyperlipidemia meds in accordance with guidelines | Hyperlipidemia meds: moderate-intensity statin, OR high-intensity statin. | Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up | |
Secondary | Rates of prescribing hypertriglyceridemia med in accordance with guidelines | Hypertriglyceridemia meds: icosapent ethyl. | Per encounter during 12 months baseline prior to intervention, 18 months intervention, and up to 18 months follow-up | |
Secondary | Depression care - Large and Small version | Patient Health Questionnaire (PHQ) -2/PHQ-9 screening completion: PHQ-2 completion rate per primary care encounter over a 12-month period. PHQ-9 completion rate per instance of positive PHQ-2 over a 12-month period. (See Depressive Symptoms for range) | Per encounter; per EHR during 12 months of baseline prior to intervention, during the 18 months of intervention period and up to 18 months of follow-up | |
Secondary | Depression care intervention | Minimally adequate treatment for depression:
Depressive disorder diagnosis rate per patient per 12-month period. Amongst patients with a depressive disorder diagnosis, percentage receiving: two or more months of an appropriate antidepressant medication plus four or more visits to any type of prescribing provider per 12-month period, OR 8 or more psychotherapy visits with any professional lasting an average of 30 minutes per 12-month period. |
Per EHR, -12 to 0 months, 1 to 12 months, 13-24 months | |
Secondary | Lifestyle counseling according to guidelines | Smoking cessation counseling
Diet counseling Physical exercise counseling |
Annual during 12 months of baseline prior to intervention, during the 18 months intervention and up to 18 months of follow-up; per EHR | |
Secondary | Presbyterian Medical Services (PMS) Patient satisfaction survey | PMS conducts routine patient satisfaction survey post each encounter. Survey is proprietary. Improvement in patient satisfaction in ECHO intervention compared with comparator. Score goes from lowest to high (scale of 1 to 5), and increase is better outcome. | Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up | |
Secondary | Health behaviors | Patient reports: (1) checking blood glucose during the last 7 days; (2) checking their feet during the last 7 days. | Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up | |
Secondary | Tobacco use | Patient reports smoking cigarettes in the last 30 days. | Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up | |
Secondary | Diet | Patient reports: (1) soda consumption in last 30 days; (2) high fat foods consumed during last 7 days; (3) spacing carbo- hydrates evenly during last 7 days | Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up | |
Secondary | Physical exercise | Patient reports physical activity of at least 30 mins during the last 7 days. | Per PMS standard patient survey; per encounter during 12 months of baseline prior to intervention, during 18 months of intervention and up to 18 months of follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |